Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Szamatowicz, J.
Right arrow Articles by Tomaszewska, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szamatowicz, J.
Right arrow Articles by Tomaszewska, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 17, No. 2, 284-288, February 2002
© 2002 European Society of Human Reproduction and Embryology

Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1: a possible role in the pathogenesis of endometriosis

J. Szamatowicz1,3, P. Laudanski1 and I. Tomaszewska2

1 Department of Gynaecology and 2 Department of Gynaecological Endocrinology, Bialystok Medical University, Bialystok, Poland

BACKGROUND: Matrix metalloproteinases (MMPs) are a family of endopeptidases which play a role in the degradation and turnover of extracellular matrix proteins. Their action is regulated by specific tissue inhibitors called tissue inhibitors of metalloproteinases (TIMPs). METHODS: We measured the concentrations of total and active MMP-9 in peritoneal fluid of infertile women with mild or moderate endometriosis (n = 22) and compared them with those in a control group of infertile patients (n = 21). RESULTS: We found that the mean (±SD) total concentrations of MMP-9 in the peritoneal fluid of patients with endometriosis was 6.2 ± 1.8 ng/ml, in comparison with 2.9 ± 2.6 ng/ml in the control group (P = 0.001). Concentrations of active MMP-9 did not differ significantly between the groups. The concentrations of TIMP-1, after logarithmic transformation, were significantly lower (P = 0.017) in endometriotic peritoneal fluids than in peritoneal fluid of control women, 1.02 ± 0.21 ng/ml and 1.16 ± 0.18 ng/ml respectively. No correlation between stage of disease, steroid hormone concentration, MMP-9 (total and active) and TIMP-1 was found. CONCLUSIONS: These results suggest that a disturbed equilibrium exists between MMP-9 and TIMP-1 in peritoneal fluid of women with endometriosis. This may play an important role in the pathogenesis of the disease.

Key words: mild-moderate endometriosis/MMP-9/peritoneal fluid/TIMP-1

3 To whom correspondence should be addressed at: Department of Gynaecology, Bialystok Medical University, ul. Marii Sklodowskiej—Curie 24a, 15–276 Bialystok, Poland. E-mail: szamatj{at}cksr.ac.bialystok.pl

Submitted on November 10, 2000; resubmitted on August 14, 2001


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
F. Minici, F. Tiberi, A. Tropea, M. Orlando, M. F. Gangale, F. Romani, S. Campo, A. Bompiani, A. Lanzone, and R. Apa
Endometriosis and human infertility: a new investigation into the role of eutopic endometrium
Hum. Reprod., March 1, 2008; 23(3): 530 - 537.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. Akoum, C. Lawson, C. Herrmann-Lavoie, and R. Maheux
Imbalance in the expression of the activating type I and the inhibitory type II interleukin 1 receptors in endometriosis
Hum. Reprod., May 1, 2007; 22(5): 1464 - 1473.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
K. Shan, Z. Lian-Fu, D. Hui, G. Wei, W. Na, J. Xia, and L. Yan
Polymorphisms in the promoter regions of the matrix metalloproteinases-7, -9 and the risk of endometriosis and adenomyosis in China
Mol. Hum. Reprod., January 1, 2006; 12(1): 35 - 39.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M.-H. Wu, Y. Shoji, M.-C. Wu, P.-C. Chuang, C.-C. Lin, M.-F. Huang, and S.-J. Tsai
Suppression of Matrix Metalloproteinase-9 by Prostaglandin E2 in Peritoneal Macrophage Is Associated with Severity of Endometriosis
Am. J. Pathol., October 1, 2005; 167(4): 1061 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
P. Laudanski, J. Szamatowicz, H. Laudanska, M. Castellanos, J. Castillo, and A. Davalos
Cellular-Fibronectin and Matrix Metalloproteinase-9 in Patients With Stroke
Stroke, January 1, 2005; 36(1): 3 - 4.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
A. W. Nap, G. A.J. Dunselman, A. F.P.M. de Goeij, J. L.H. Evers, and P. G. Groothuis
Inhibiting MMP activity prevents the development of endometriosis in the chicken chorioallantoic membrane model
Hum. Reprod., October 1, 2004; 19(10): 2180 - 2187.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J. Gilabert-Estelles, A. Estelles, J. Gilabert, R. Castello, F. Espana, C. Falco, A. Romeu, M. Chirivella, E. Zorio, and J. Aznar
Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis
Hum. Reprod., July 1, 2003; 18(7): 1516 - 1522.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.